Semnur Pharmaceuticals, Inc.
SMNR
$8.00
$0.000.00%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 157.87M | 152.97M | 2.58M | 2.89M | 2.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 160.42M | 155.03M | 3.74M | 3.85M | 4.69M |
| Operating Income | -160.42M | -155.03M | -3.74M | -3.85M | -4.69M |
| Income Before Tax | -160.42M | -155.03M | -3.74M | -3.85M | -4.69M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -160.42 | -155.03 | -3.74 | -3.85 | -4.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -160.42M | -155.03M | -3.74M | -3.85M | -4.69M |
| EBIT | -160.42M | -155.03M | -3.74M | -3.85M | -4.69M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.80 | -0.77 | -0.02 | -0.02 | -0.03 |
| Normalized Basic EPS | -0.50 | -0.48 | -0.01 | -0.01 | -0.02 |
| EPS Diluted | -0.80 | -0.77 | -0.02 | -0.02 | -0.03 |
| Normalized Diluted EPS | -0.50 | -0.48 | -0.01 | -0.01 | -0.02 |
| Average Basic Shares Outstanding | 739.12M | 721.69M | 720.00M | 720.00M | 720.00M |
| Average Diluted Shares Outstanding | 739.12M | 721.69M | 720.00M | 720.00M | 720.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |